Evaporative vs aqueous deficient dry eye: the difference

Dry eye is usually split into two types. Evaporative dry eye is where tears are produced but evaporate too quickly, almost always because the oil glands in the eyelids are not delivering enough usable lipid. Aqueous deficient dry eye is where the lacrimal gland does not make enough tear fluid. Evaporative is much more common.

The more accurate picture is that these are not two boxes. The TFOS DEWS II classification of 2017 places aqueous deficient and evaporative dry eye on a continuum, so that elements of each are considered in diagnosis and management.

The distinction matters because it changes what you do. Warming the eyelids is the right first move for one and largely beside the point for the other.

What the definition actually says

The 2017 definition treats dry eye as a multifactorial disease in which loss of homeostasis of the tear film is the central concept. It names tear film instability, hyperosmolarity, and ocular surface inflammation and damage as the key causes, and adds neurosensory abnormalities. The classification also makes room for non-obvious disease, where surface signs exist without matching symptoms, and for the reverse case, where symptoms exist without demonstrable signs.

Evaporative dry eye: when the oil fails

The TFOS DEWS II tear film review describes the tear film as a mixture of lipids, proteins, mucins and electrolytes, all contributing to its integrity. Clinically, the review notes, dry eye is characterised by loss of tear volume, faster break-up, and increased evaporation from the ocular surface.

The lipid comes from the meibomian glands in the eyelids, and when those glands become obstructed, the oil layer thins and evaporation rises. Blackie and colleagues' review describes obstructive meibomian gland dysfunction as the most common recognised cause of evaporative dry eye, and notes it is frequently nonobvious, with signs absent unless specific examination techniques are used.

The oil itself changes too. Borchman and colleagues measured the thermal behaviour of human meibum and found the phase-transition temperature was significantly higher, by about 4 °C, in gland dysfunction than in age-matched donors with no history of dry eye symptoms, with 82% of affected samples above the normal range. The oil is stiffer and needs more warmth to flow, which is why heat is a first-line measure on this side. Blink quality matters too: Wang and colleagues found people with clinically detectable incomplete blinking had around twice the odds of meeting the dry eye criteria. There is more in our guide to tear film layers and in what meibomian gland dysfunction is.

Aqueous deficient dry eye: when the water runs short

Here the problem is volume. The lacrimal gland, above and behind the outer part of the upper lid, is not producing enough of the watery component. Causes include ageing lacrimal tissue, autoimmune disease, some prescription medicines and scarring. The autoimmune association changes management most: Sjögren disease affects the lacrimal and salivary glands together, so persistent dry eye alongside a dry mouth, joint pain or an existing autoimmune diagnosis deserves investigation.

Both routes end up in the same place. The TFOS DEWS II pathophysiology review names evaporative water loss leading to hyperosmolar tissue damage as the central mechanism, describes the resulting loss of epithelial and goblet cells, and explains how the fall in surface wettability leads to early break-up and amplifies hyperosmolarity through what it calls a vicious circle.

How common each one is

Lemp and colleagues addressed this in 2012, examining Schirmer results and meibomian gland dysfunction grades in 299 subjects across ten sites in the European Union and the United States. Of 224 classified as having dry eye disease, 159 fell into one of three defined categories: 79 with gland dysfunction only, 57 with both gland dysfunction and aqueous deficiency, and just 23 who were purely aqueous deficient. Overall, 86% of those qualified patients showed signs of gland dysfunction; the remaining 65 showed dry eye through other clinical signs without overt evidence of either subtype.

Their conclusion was that in a general clinic-based cohort, evaporative dry eye from gland dysfunction far outweighs pure aqueous deficiency. The TFOS DEWS II epidemiology review found reported prevalence ranging from 5% to 50% depending on population and definition, rising with age and higher in women, although the sex difference became significant only with age.

How they are told apart in the chair

The recommended sequence starts with questions, not instruments. The TFOS DEWS II diagnostic review advises triaging questions first, to exclude conditions that mimic dry eye, then symptom screening with a questionnaire such as the DEQ-5 or the OSDI. A positive screen triggers the tests: tear break-up time, ideally measured non-invasively, tear osmolarity, and ocular surface staining with fluorescein and lissamine green across the cornea, conjunctiva and eyelid margin.

Only after dry eye is confirmed does sub-classification happen, using assessment of meibomian gland dysfunction, lipid layer thickness and dynamics, and tear volume. Individual tests are less decisive than their reputations suggest. Tear osmolarity performed best as a single measure in a ten-site study of 314 people, and the tests most people have heard of performed worse; our guide to dry eye tests explained covers what each one can and cannot settle.

Why the treatment differs, and what mixed disease means

The TFOS DEWS II management review derived a staged algorithm stepping through options by severity, and concluded that differentiating aqueous deficient from evaporative disease was critical in selecting the most appropriate strategy. The same review was candid that many dry eye treatments lack the Level 1 evidence needed to recommend them confidently, and that predicting the benefit of a given option for a given subtype remains difficult.

On the evaporative side the logic is mechanical: stiff meibum needs warming before it will flow. Olson and colleagues applied a warm moist compress at 40.0 ± 2.0 °C to the closed lids of one eye in 20 patients with gland dysfunction, with a room-temperature compress on the other eye as control, and found tear film lipid layer thickness rose by more than 80% within five minutes and a further 20% after fifteen, with no significant change in the control eye. Getting the heat to the inner lid is the hard part, and measurements of the inner eyelid surface show it is a question of sustained contact rather than a hotter source. Warmth is then followed by lid hygiene and, where appropriate, gland expression.

On the aqueous deficient side, warming a lid that already delivers adequate oil achieves very little. The work is in supplementing and retaining the tear volume that is there, reviewing medications that may be reducing it, and identifying any systemic cause. If Sjögren disease is suspected, that referral matters more than any drop.

The pathophysiology review states plainly that hybrid disease with features of both aqueous deficiency and increased evaporation is common, and that efforts should be made to determine the relative contribution of each. In practice that means treating the dominant mechanism first and reassessing, rather than choosing a side. Our guide to what type of dry eye you have walks through the symptom patterns.

If your assessment points to the evaporative side, a heated eye mask is a way of getting the same warmth, at the same setting, for the same length of time, every session. The Meibocare E-Heated Eye Mask is designed to bring the eyelids to about 42 °C on the recommended setting and timer, with three settings each paired with a timer: 20 minutes on Low, 15 on Medium, 10 on High. It is notified to Medsafe on the New Zealand WAND database (240927-WAND-746QNT), a register that records notification rather than assessing performance. It addresses the evaporative and meibomian gland side only; if your problem is aqueous deficiency, heat is not the answer and you need a different plan. If you have an active eye infection, have had recent eye surgery, have glaucoma, or notice any change in your vision, speak to your optometrist or ophthalmologist before starting or continuing heat therapy.

Frequently asked questions

What is the difference between evaporative and aqueous deficient dry eye?

Evaporative dry eye means tears are produced but evaporate too quickly, usually because obstructed meibomian glands are not supplying enough oil to the tear film. Aqueous deficient dry eye means the lacrimal gland is not producing enough watery tear fluid. The 2017 TFOS DEWS II classification treats the two as a continuum rather than separate conditions, with most people showing elements of both.

Which type of dry eye is more common?

Evaporative, by a wide margin. In a clinic-based study across ten sites, 159 patients with dry eye were sorted into three groups: 79 had meibomian gland dysfunction only, 57 had both gland dysfunction and aqueous deficiency, and 23 were purely aqueous deficient. Overall 86% of the classified patients showed signs of gland dysfunction.

Can you have both types of dry eye at once?

Yes, and it is common. The TFOS DEWS II pathophysiology review states that hybrid disease with features of both aqueous deficiency and increased evaporation is common, and recommends working out the relative contribution of each. In one clinic cohort the mixed group was more than twice the size of the pure aqueous deficient group.

Does a heated eye mask help both types of dry eye?

No. Heat targets the evaporative side, where the aim is to warm stiff meibum so obstructed glands can deliver oil again. Warming eyelids that are already producing adequate oil does little for a tear volume problem. Aqueous deficient disease is managed by supplementing and retaining tear volume and by addressing any underlying systemic cause.

Educational information only, not medical advice. References: Craig JP, et al. Ocul Surf. 2017;15:276–283; Bron AJ, et al. Ocul Surf. 2017;15:438–510; Willcox MDP, et al. Ocul Surf. 2017;15:366–403; Wolffsohn JS, et al. Ocul Surf. 2017;15:539–574; Stapleton F, et al. Ocul Surf. 2017;15:334–365; Jones L, et al. Ocul Surf. 2017;15:575–628; Lemp MA, et al. Cornea. 2012;31:472–478; Lemp MA, et al. Am J Ophthalmol. 2011;151:792–798; Blackie CA, et al. Cornea. 2010;29:1333–1345; Borchman D, et al. Invest Ophthalmol Vis Sci. 2011;52:3805–3817; Wang MTM, et al. Ocul Surf. 2018;16:424–429; Olson MC, et al. Eye Contact Lens. 2003;29:96–99; Blackie CA, et al. Optom Vis Sci. 2008;85:675–683.